Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Akers Biosciences (AKER)

Akers Biosciences (AKER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,133
  • Shares Outstanding, K 16,653
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,580 K
  • 60-Month Beta 0.33
  • Price/Sales -114.26
  • Price/Cash Flow N/A
  • Price/Book 1.26
Trade AKER with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.07
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/21/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.40 +2.73%
on 04/16/21
4.09 -39.61%
on 03/19/21
-1.20 (-32.70%)
since 03/16/21
3-Month
2.40 +2.73%
on 04/16/21
5.24 -52.86%
on 02/16/21
-0.18 (-6.79%)
since 01/15/21
52-Week
1.65 +49.70%
on 11/11/20
6.97 -64.56%
on 08/10/20
-1.17 (-32.14%)
since 04/16/20

Most Recent Stories

More News
Contango Announces the Appointment of Two New Directors

FORT WORTH, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) today announced the appointment of Karen Simon and Janet Pasque...

MCF : 3.22 (+3.54%)
ENOG.LN : 1,259.000 (+1.86%)
AKER : 4.94 (-9.52%)
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

Akers Biosciences, Inc. (“Akers”) (Nasdaq: AKER) and MyMD Pharmaceuticals, Inc. (“MYMD”) today announced that at Akers’ special meeting of stockholders held on April 15, 2021, Akers obtained...

AKER : 4.94 (-9.52%)
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial

Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health...

AKER : 4.94 (-9.52%)
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board

Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy...

AKER : 4.94 (-9.52%)
Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals

Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals...

AKER : 4.94 (-9.52%)
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery

Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing...

AKER : 4.94 (-9.52%)
Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission

Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing...

AKER : 4.94 (-9.52%)
Akers Biosciences Responds to Erroneous Earnings Call Press Release

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the...

AKER : 4.94 (-9.52%)
AKERS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKER and Encourages Investors to Contact the Firm

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akers Biosciences,...

AKER : 4.94 (-9.52%)
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages HMSY, HCAP, CBMG, and AKER Shareholders to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 2, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: HMS Holdings Corp. (NASDAQ:HMSY) concerning potential...

HMSY : 36.98 (+0.01%)
HCAP : 9.66 (+1.68%)
CBMG : 19.75 (unch)
AKER : 4.94 (-9.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Akers Biosciences, Inc. develops, manufactures and supplies rapid, point-of-care screening and testing products. The Company's products primarily includes BreathScan(R), BreathScan PRO(R), METRON(R), VIVO(TM), Heparin/PF4 Antibody Serum Panels(R) and Breath Ketone. Akers Biosciences, Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.27
1st Resistance Point 2.87
Last Price 4.94
1st Support Level 2.24
2nd Support Level 2.00
3rd Support Level 1.60

See More

52-Week High 6.97
Fibonacci 61.8% 4.94
Last Price 4.94
Fibonacci 50% 4.31
Fibonacci 38.2% 3.68
52-Week Low 1.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar